Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Daumke, Oliver Prof. Dr. (1) Franke, Vedran Dr. (1) Hübner, Norbert Prof. Dr. (2) Janz, Martin Dr. (5) Kolesnichenko, Marina Dr. (1) Leutz, Achim Prof. Dr. (1) Patone, Giannino Dr. (2) Rajewsky, Klaus Prof. Dr. (1) Scheidereit, Claus Prof. Dr. (3) Selbach, Matthias Prof. Dr. (1) Wollert-Wulf, Brigitte (1) (-) Mathas, Stephan Dr. (11) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) 2004 (2) (-) 2005 (2) 2006 (4) 2007 (3) 2008 (4) 2009 (3) 2010 (3) 2011 (4) 2012 (1) 2013 (1) 2014 (2) (-) 2015 (5) (-) 2016 (2) 2017 (3) 2018 (1) (-) 2019 (2) 2020 (2) 2021 (3) 2022 (4) 2023 (8) 2024 (1) AG Schreiber [ECRC] (1) Bioinformatics and Omics Data Science (1) (-) Biology of Malignant Lymphomas (11) Cellular Neurosciences (2) Experimental Ultrahigh-Field MR (17) Genetics and Genomics of Cardiovascular Diseases (2) Innate Immunity & Neuroinflammation (2) Magnetic Resonance (17) Molecular Biology of Peptide Hormones (1) Nephrology and Inflammatory Vascular Diseases (1) Proteome Dynamics (1) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) 11 Results: Active Filter: Mathas, Stephan Dr.Biology of Malignant Lymphomas2005201520162019 Sort: Result score Newest to oldest Oldest to newest July 01, 2016 / Semin Hematol Hodgkin lymphoma: pathology and biology S. Mathas S. Hartmann R. Küppers January 01, 2005 / Blood A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas F. Jundt N. Raetzel C. Mueller C.F. Calkhoven K. Kley S. Mathas A. Lietz A. Leutz B. Doerken August 25, 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit June 01, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer March 17, 2016 / Genome Med A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses K.A.P. de Oliveira E. Kaergel M. Heinig J.F. Fontaine G. Patone E.M. Muro S. Mathas M. Hummel M.A. Andrade-Navarro N. Hübner C. Scheidereit May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas June 01, 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert Pagination Current page 1 Page 2 Next page Next › Last page Last »
July 01, 2016 / Semin Hematol Hodgkin lymphoma: pathology and biology S. Mathas S. Hartmann R. Küppers
January 01, 2005 / Blood A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas F. Jundt N. Raetzel C. Mueller C.F. Calkhoven K. Kley S. Mathas A. Lietz A. Leutz B. Doerken
August 25, 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken
March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit
June 01, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer
March 17, 2016 / Genome Med A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses K.A.P. de Oliveira E. Kaergel M. Heinig J.F. Fontaine G. Patone E.M. Muro S. Mathas M. Hummel M.A. Andrade-Navarro N. Hübner C. Scheidereit
May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert